Needham Reiterates Buy on Taysha Gene Therapies, Maintains $10 Price Target
Benzinga Newsdesk 1 year ago
NewsPrice TargetReiterationAnalyst Ratings
Needham analyst Gil Blum reiterates Taysha Gene Therapies (NASDAQ:TSHA) with a Buy and maintains $10 price target.
Needham analyst Gil Blum reiterates Taysha Gene Therapies (NASDAQ:TSHA) with a Buy and maintains $10 price target.